Physician profile
Michael G Zahn
NPI 1437118247
$45,002.38
in general payments reported to CMS, 2019-2025
14 companies · $72.81 in 2025
The $72.81 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $64.53 · 2021: $424 · 2022: $1,502 · 2023: $42K · 2024: $128 · 2025: $72.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $42K · Food and Beverage: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $41,960.13 |
| Food and Beverage | $179.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $42,040.22 | 2019-2025 | Tapestry |
| Lima USA, INC. | $2,049.48 | 2019-2022 | |
| Smith+Nephew, INC. | $406.77 | 2021 | |
| Horizon Therapeutics Plc | $138.58 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $71.15 | 2023-2024 | Iovera, Exparel, Zilretta |
| Medacta USA, INC. | $58.18 | 2022-2023 | Gmk Sphere |
| Depuy Synthes Sales INC. | $57.74 | 2020-2024 | Monovisc, Orthovisc |
| Stryker Corporation | $46.54 | 2019 | |
| Intrinsic Therapeutics | $33.45 | 2023 | Barricaid Acd (Annular Closure Device) |
| Acelrx Pharmaceuticals, INC. | $32.79 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $25.21 | 2024 | |
| Stimwave Technologies Incorporated | $16.36 | 2020 | |
| Next Science LLC | $15.30 | 2022 | |
| Fidia Pharma USA INC. | $10.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$141,707.28 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.